Lipoprotein(a) levels are associated with aortic valve calcification in asymptomatic patients with familial hypercholesterolaemia

Journal of Internal Medicine

Volumn 278, Issue 2, 2015, Pages 166-173

  Vongpromek, R ^a   Bos, S ^a   ten Kate, G J R ^b   Yahya, R ^a   Verhoeven, A J M ^a   de Feyter, P J ^b   Kronenberg, F ^c   Roeters van Lennep, J E ^a   Sijbrands, E J G ^a   Mulder, Monique T ^a  

^a Department of Internal Medicine   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

aortic valve calcification; asymptomatic; coronary artery calcification; familial hypercholesterolaemia; lipoprotein(a)

Indexed keywords

APOLIPOPROTEIN A; CALCIUM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A;

ADULT; AGE; AGED; AORTA VALVE DISEASE; AORTIC VALVE CALCIFICATION; ARTICLE; BODY MASS; CALCIFICATION; CARDIOVASCULAR RISK; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONFIDENCE INTERVAL; COPY NUMBER VARIATION; CORONARY ARTERY CALCIFICATION; CORONARY ARTERY CALCIUM SCORE; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG USE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; KRINGLE DOMAIN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; REFERENCE VALUE; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; AORTA VALVE; AORTIC VALVE STENOSIS; BLOOD; CALCINOSIS; COMPLICATION; INCIDENCE; MIDDLE AGED; NETHERLANDS; PATHOLOGY; RETROSPECTIVE STUDY;

ADULT; AGED; AORTIC VALVE; AORTIC VALVE STENOSIS; CALCINOSIS; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; INCIDENCE; LIPOPROTEIN(A); MALE; MIDDLE AGED; NETHERLANDS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84942416178     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12335     Document Type: Article

References (48)

1. Lindroos M, Kupari M, Heikkila J, Tilvis R. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol 1993; 21: 1220–5.
2. Utsunomiya H, Yamamoto H, Kunita E et al. Combined presence of aortic valve calcification and mitral annular calcification as a marker of the extent and vulnerable characteristics of coronary artery plaque assessed by 64-multidetector computed tomography. Atherosclerosis 2010; 213: 166–72.
3. Blaha MJ, Budoff MJ, Rivera JJ et al. Relation of aortic valve calcium detected by cardiac computed tomography to all-cause mortality. Am J Cardiol 2010; 106: 1787–91.
4. Cueff C, Serfaty JM, Cimadevilla C et al. Measurement of aortic valve calcification using multislice computed tomography: correlation with haemodynamic severity of aortic stenosis and clinical implication for patients with low ejection fraction. Heart 2011; 97: 721–6.
5. Rajamannan NM. Mechanisms of aortic valve calcification: the LDL-density-radius theory: a translation from cell signaling to physiology. Am J Physiol Heart Circ Physiol 2010; 298: H5–15.
6. Kronenberg F, Utermann G. Lipoprotein(a): resurrected by genetics. J Intern Med 2013; 273: 6–30.
7. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000; 102: 1082–5.
8. Erqou S, Thompson A, Di Angelantonio E et al. Apolipoprotein(a) isoforms and the risk of vascular disease systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol 2010; 55: 2160–7.
9. Seed M, Hoppichler F, Reaveley D et al. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med 1990; 322: 1494–9.
10. Holmes DT, Schick BA, Humphries KH, Frohlich J. Lipoprotein(a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia. Clin Chem 2005; 51: 2067–73.
11. Jansen ACM, Aalst-Cohen ES, Tanck MW et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med 2004; 256: 482–90.
12. Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol 2014; 63: 470–7.
13. Thanassoulis G, Campbell CY, Owens DS et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med 2013; 368: 503–12.
14. O'Brien KD, Reichenbach DD, Marcovina SM, Kuusisto J, Alpers CE, Otto CM. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of ‘degenerative’ valvular aortic stenosis. Arterioscler Thromb Vasc Biol 1996; 16: 523–32.
15. Stewart BF, Siscovick D, Lind BK et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 1997; 29: 630–4.
16. Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Elevated Lipoprotein(a) and Risk of Aortic Valve Stenosis in the General Population. J Am Coll Cardiol 2014; 63: 470–7.
17. ten Kate GJ, Neefjes LA, Dedic A et al. The effect of LDLR-negative genotype on CT coronary atherosclerosis in asymptomatic statin treated patients with heterozygous familial hypercholesterolemia. Atherosclerosis 2013; 227: 334–41.
18. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990; 15: 827–32.
19. Jiang Y, Guo K, Chen M, Bao J, Shen C, Li Y. Serum lipoprotein(a) positively correlates with coronary artery calcification in low-risk chinese han patients: a study from a single center. PLoS One 2013; 8: e71673.
20. Haq AM, Giasuddin ASM, Huque MM. Serum total homocysteine and lipoprotein(a) levels in acute myocardial infarction and their response to treatment with vitamins. J Coll Physicians Surg Pak 2011; 21: 266–70.
21. Kronenberg F, Lobentanz EM, König P, Utermann G, Dieplinger H. Effect of sample storage on the measurement of lipoprotein [a], apolipoproteins B and A-IV, total and high density lipoprotein cholesterol and triglycerides. J Lipid Res 1994; 35: 1318–28.
22. Kronenberg F, Kuen E, Ritz E et al. Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol 2000; 11: 105–15.
23. Hoeg JM, Feuerstein IM, Tucker EE. Detection and quantitation of calcific atherosclerosis by ultrafast computed tomography in children and young adults with homozygous familial hypercholesterolemia. Arterioscler Thromb 1994; 14: 1066–74.
24. Antonini-Canterin F, Popescu BA, Huang G et al. Progression of aortic valve sclerosis and aortic valve stenosis: what is the role of statin treatment? Ital Heart J 2005; 6: 119–24.
25. Berglund L, Ramakrishnan R. Lipoprotein(a): an elusive cardiovascular risk factor. Arterioscler Thromb Vasc Biol 2004; 24: 2219–26.
26. Bozbas H, Yildirir A, Atar I et al. Effects of serum levels of novel atherosclerotic risk factors on aortic valve calcification. J Heart Valve Dis 2007; 16: 387–93.
27. Versmissen J, Oosterveer DM, Yazdanpanah M et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008; 337: a2423.
28. Neefjes LA, ten Kate GJ, Alexia R et al. Accelerated subclinical coronary atherosclerosis in patients with familial hypercholesterolemia. Atherosclerosis 2011; 219: 721–7.
29. Khera AV, Everett BM, Caulfield MP et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation 2014; 129: 635–42.
30. Kronenberg F, Neyer U, Lhotta K et al. The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients a prospective follow-up. J Am Soc Nephrol 1999; 10: 1027–36.
31. Longenecker JC, Klag MJ, Marcovina SM et al. High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients. J Am Soc Nephrol 2005; 16: 1794–802.
32. Wexler L, Brundage B, Crouse J et al. Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professionals from the American Heart Association. Circulation 1996; 94: 1175–92.
33. Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation 2005; 111: 3316–26.
34. Demer LL, Tintut Y. Vascular calcification pathobiology of a multifaceted disease. Circulation 2008; 117: 2938–48.
35. Mahabadi AA, Bamberg F, Toepker M et al. Association of aortic valve calcification to the presence, extent, and composition of coronary artery plaque burden: from the Rule Out Myocardial Infarction using Computer Assisted Tomography (ROMICAT) trial. Am Heart J 2009; 158: 562–8.
36. Koulaouzidis G, Nicoll R, Macarthur T, Jenkins PJ, Henein MY. Coronary artery calcification correlates with the presence and severity of valve calcification. Int J Cardiol 2013; 168: 5263–6.
37. Achenbach S, Moselewski F, Ropers D et al. Detection of calcified and noncalcified coronary atherosclerotic plaque by contrast-enhanced, submillimeter multidetector spiral computed tomography: a segment-based comparison with intravascular ultrasound. Circulation 2004; 109: 14–7.
38. Shavelle DM, Takasu J, Budoff MJ, Mao S, Zhao XQ, O'Brien KD. HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet 2002; 359: 1125–6.
39. Wu B, Elmariah S, Kaplan FS, Cheng G, Mohler ER 3rd. Paradoxical effects of statins on aortic valve myofibroblasts and osteoblasts: implications for end-stage valvular heart disease. Arterioscler Thromb Vasc Biol 2005; 25: 592–7.
40. Rossebø AB, Pedersen TR, Boman K et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008; 359: 1343–56.
41. Gilmanov D, Bevilacqua S, Mazzone A, Glauber M. Do statins slow the process of calcification of aortic tissue valves? Interact Cardiovasc Thorac Surg 2010; 11: 297–301.
42. Kronenberg F. Lipoprotein(a): there's life in the old dog yet. Circulation 2014; 129: 619–21.
43. Callister TQ, Raggi P, Cooil B, Lippolis NJ, Russo DJ. Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med 1998; 339: 1972–8.
44. Achenbach S, Ropers D, Pohle K et al. Influence of lipid-lowering therapy on the progression of coronary artery calcification a prospective evaluation. Circulation 2002; 106: 1077–82.
45. Kostner GM, Avogaro P, Cazzolato G, Marth E, Bittolo-Bon G, Qunici GB. Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis 1981; 38: 51–61.
46. Nordestgaard BG, Chapman MJ, Ray K et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010; 31: 2844–53.
47. Carmena R, Lussier-Cacan S, Roy M et al. Lp(a) levels and atherosclerotic vascular disease in a sample of patients with familial hypercholesterolemia sharing the same gene defect. Arterioscler Thromb Vasc Biol 1996; 16: 129–36.
48. Alonso R, Andres E, Mata N et al. Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J Am Coll Cardiol 2014; 63: 1982–9.